Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staff
Five-year cumulative data from two trials of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) demonstrated high rates of viral suppression that were durable without the emergence of resistance, according to a presentation at AIDS 2022 (poster EPB150).
Studies 1489 and 1490 are phase 3, randomized, double-blind, active-controlled trials comparing treatment-naive